Remove 2018 Remove Licensing Remove Regulations
article thumbnail

Article FDA Thank You Following a 2018 draft framework, FDA unveils long-awaited PDURS draft guidance

Agency IQ

Following a 2018 draft framework, FDA unveils long-awaited PDURS draft guidance A long-awaited draft guidance on Prescription Drug Use-Related Software (PDURS) outlines when information from digital health tools could be represented on prescription drug labeling. See AgencyIQ’s full analysis of the 2018 framework, and industry response, here.]

FDA 40
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Trends Immunol 39(6):446-459 (2018). Nat Commun 9(1):1760 (2018). Normality sensing licenses local T cells for innate-like tissue surveillance. Regulation of cutaneous malignancy by gammadelta T cells. J Front Immunol 9:1409 (2018). Davey M, Willcox C, Baker A, et al. Davey M, Willcox C, Hunter S, et al.

Therapies 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Trends in Pharmaceutical Mergers and Acquisitions

DrugBank

However, ensuring that these structures comply with applicable tax laws and regulations is essential to avoid potential legal and reputational risks. This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams.

article thumbnail

A Final LDT Rule in April!? Will FDA be prepared?

FDA Law Blog: Biosimilars

1] Yet FDA’s conclusions about the Agency’s ability to regulate the entire laboratory industry are based on fundamentally flawed assumptions about the number of entities and tests that will be subject to FDA regulation. This is based on FDA’s reported 2018 review of the CLIA database. [2]

FDA 69
article thumbnail

Analysis Life Sciences Thank You Updated guidance on promotional labeling for biosimilars and interchangeables emphasizes a similar approach

Agency IQ

In 2018, the FDA published a detailed guidance on labeling requirements for biosimilar products. However, the 2018 guidance it did not offer advice for interchangeable product labeling. regarding its administration, preparation, storage, or safety). However, the guidance didn’t offer recommendations on promotional materials.

article thumbnail

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

The Pharma Data

Syndesi’s unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018.

article thumbnail

DOJ Investigates $250 Million in U.S. Sales of Counterfeit Drugs Using Fake DSCSA Pedigrees

Policy Prescription

from licensed pharmacies to American patients. Instead, it had everything to do with licensed U.S. Even worse, it showed flaws in our domestic system of drug regulation, notably the Drug Supply Chain Security Act of 2013 (DSCSA). However, to do that, the regulations must prevent the creation of fake DSCSA pedigrees.